ReviewDrugs2007
Fixed-dose combination lercanidipine/enalapril.
Review in Drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01211314 (Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial.Journal of hypertension · 2014Trial
- Hydrolyzed Collagen from Salmon Skin Mitigates L-NAME-Induced Hypertension in Rats by Attenuating Oxidative Stress and Inflammation and Improving Vascular Remodeling.International journal of molecular sciences · 2026Article
- Cocrystal of Apixaban-Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs.Molecules (Basel, Switzerland) · 2021Article
- Determination of lercanidipine in human plasma by an improved UPLC-MS/MS method for a bioequivalence study.Journal of pharmaceutical analysis · 2016Article
- Lercanidipine/enalapril combination in the management of obesity-related hypertension.Integrated blood pressure control · 2016Review
- Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.Vascular health and risk management · 2016Review
- Use of combination antihypertensive therapy initiation in older Americans without prevalent cardiovascular disease.Journal of the American Geriatrics Society · 2014Observational
- Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal.Drugs in R&D · 2014Observational
- Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence.Patient preference and adherence · 2012Article
- Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.Clinical drug investigation · 2010Review
- Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.Vascular health and risk management · 2008Review
- Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.Vascular health and risk management · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lercanidipine, a dihydropyridine calcium channel blocker, and enalapril, an ACE inhibitor, are established antihypertensive agents. A fixed-dose tablet formulation of lercanidipine/enalapril is approved in Germany for the treatment of hypertension in patients not responding to monotherapy. Lercanidipine/enalapril 10mg/10mg once daily significantly reduced sitting diastolic blood pressure and sitting systolic blood pressure, relative to lercanidipine 10mg once daily, in a 12-week, randomised, double-blind trial in patients with mild to moderate hypertension who had previously not responded to 4 weeks' treatment with lercanidipine. In a similarly designed trial, lercanidipine/enalapril 10mg/20mg once daily was significantly more effective than enalapril 20mg once daily in hypertensive patients who had previously not responded to enalapril monotherapy. Fixed-dose lercanidipine/enalapril was generally well tolerated, with a tolerability profile similar to that of either of the individual drugs alone or placebo. Cough was reported in <or=5.2% and peripheral oedema in <or=1.5% of lercanidipine/enalapril recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.